SLNCF
What one share of Silence Therapeutics holds
Pharmaceutical Preparations
We are a biotechnology company focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid, or siRNA, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need.
Silence Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$0.42 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.30 |
| Cash and investments | $0.51 |
| Book value | $0.27 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $0.22 | −$0.52 | $0.00 | −$0.59 | — | $0.25 |
| 2023 | $0.28 | −$0.49 | $0.00 | −$0.45 | — | $0.19 |
| 2024 | $0.31 | −$0.33 | $0.00 | −$0.49 | — | $0.95 |
| 2025 | $0.00 | −$0.63 | $0.00 | −$0.44 | — | $0.44 |